Pharmaceutical Manufacturing Technology Centre

The Pharmaceutical Manufacturing Technology Centre (PMTC) is hosted by the University of Limerick with core funding from the Irish government (Enterprise Ireland and the IDA Ireland). Income is supplemented with co-funding from industry and other public sources. PMTC, established in December 2013, is led by an industry steering board with an active research program informed by its industry members. Companies access PMTC to create projects and execute world-beating industry-relevant research in advanced technology solutions to address contemporary manufacturing issues.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS

AZZUR GROUP ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

Azzur Group, LLC | January 13, 2022

news image

To support rapid company growth and best meet the demands of the business, Azzur Group announces new executive leadership appointments. Originally founded in Philadelphia in 2010, Azzur is a market-leading provider of GxP services for the pharmaceutical, biotechnology, medical device, and healthcare industries with offices and on-demand cleanrooms locations throughout the United States. Today, the organization provides comprehensive GxP solutions through its on-demand cleanrooms, consulting and ...

Read More

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

PharmaNewsIntelligence | March 11, 2020

news image

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More

PHARMACY MARKET

AIKIDO PHARMA ANNOUNCES STRATEGIC INTEREST IN ASP ISOTOPES INC.

AIkido Pharma Inc. | December 07, 2021

news image

AIkido Pharma Inc. announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems dur...

Read More

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

news image

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More
news image

BUSINESS INSIGHTS

AZZUR GROUP ANNOUNCES EXECUTIVE LEADERSHIP CHANGES

Azzur Group, LLC | January 13, 2022

To support rapid company growth and best meet the demands of the business, Azzur Group announces new executive leadership appointments. Originally founded in Philadelphia in 2010, Azzur is a market-leading provider of GxP services for the pharmaceutical, biotechnology, medical device, and healthcare industries with offices and on-demand cleanrooms locations throughout the United States. Today, the organization provides comprehensive GxP solutions through its on-demand cleanrooms, consulting and ...

Read More
news image

FIRST GENE THERAPY CLINICAL TRIAL TO ADDRESS GENETIC BLINDNESS

PharmaNewsIntelligence | March 11, 2020

Oregon Health & Science University (OHSU) held the first-ever gene therapy clinical trial, BRILLIANCE, to address blindness-causing gene mutation, LCA10, according to a recent press release The clinical trial, sponsored by Allergan plc and Editas Medicine, is one of 14 different clinical trials investigating new genetic treatments for ophthalmic conditions and nearly 50 vision-related clinical trials. The procedure uses gene-editing tool CRISPR to edit human genes, also known as in vivo gene...

Read More
news image

PHARMACY MARKET

AIKIDO PHARMA ANNOUNCES STRATEGIC INTEREST IN ASP ISOTOPES INC.

AIkido Pharma Inc. | December 07, 2021

AIkido Pharma Inc. announced that the Company secured a strategic equity interest in ASP Isotopes, Inc., which focuses on the non-nuclear supply of enriched isotopes. ASP Isotopes' Aerodynamic Separation Process is a method of enriching molybdenum-100 which is a stable isotope of molybdenum. Technetium-99m is the most used radioisotope in the nuclear imaging industry, but the supply chain, which involves the radioactive decay of molybdenum-99 has been fraught with problems dur...

Read More
news image

JUBILANT RADIOPHARMA AND SOFIE BIOSCIENCES INK STRATEGIC COLLABORATION AGREEMENT TO FURTHER ADVANCE THE FIELD OF MOLECULAR IMAGING & THERAPEUTICS

SOFIE Biosciences, Inc. | November 05, 2020

SOFIE Biosciences, Inc. ("SOFIE"), an established radiopharmaceutical supplier and worldwide radiopharmaceutical contract manufacturing organization, and Jubilant Radiopharma, a business division of Jubilant Pharma Limited, announced that both the organizations have entered into a strategic partnership. Under the terms of the partnership, Jubilant Pharma, via one of its wholly owned subsidiaries, with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to contin...

Read More